Calcium and magnesium use for oxaliplatin-induced neuropathy: A case study to assess how quickly evidence translates into practice

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 9, 2015, Pages 1097-1101

  Pachman, Deirdre R ^a   Ruddy, Kathryn ^a   Sangaralingham, Lindsey R ^a   Grothey, Axel ^a   Shah, Nilay D ^a,b   Beutler, Andreas S ^a   Hubbard, Joleen M ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

^b OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CETUXIMAB; CISPLATIN; MAGNESIUM; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EVIDENCE BASED PRACTICE; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHY; NEUROTOXICITY; ADMINISTRATIVE CLAIMS (HEALTH CARE); CHEMICALLY INDUCED; MEDICAL RESEARCH; MINNESOTA; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TRANSLATIONAL RESEARCH; TRENDS;

ADMINISTRATIVE CLAIMS, HEALTHCARE; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CALCIUM; CETUXIMAB; CISPLATIN; HUMANS; MAGNESIUM; MINNESOTA; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84941752797     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0134     Document Type: Article

References (21)

1. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-2297.
2. Gamelin E, Gamelin L, Delva R, et al. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: a retrospective study [abstract]. Proc Am Soc Clin Oncol 2002;21:157a. Abstract 624.
3. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055-4061.
4. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007;25:4028-4029.
5. Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008;26:1188-1189; author reply 1189-1190.
6. Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 4010.
7. Nikcevich DA, Grothey A, Sloan JA, et al. Intravenous calcium and magnesium prevents oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: results of a phase III placebo-controlled, double-blind trial (N04C7) [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 4009.
8. Grothey A, Nikcevich DA, Sloan JA, et al. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: results from a placebo-controlled phase III trial. J Clin Oncol 2009;27(Suppl):Abstract 4025.
9. Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011;29:421-427. Published online ahead of print December 28, 2010.
10. Loprinzi CL Qin R, Dakhil SR, et al. Phase III randomized, placebo (PL) - controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: an alliance for clinical trials in oncology study. J Clin Oncol 2013;31(Suppl):Abstract 3501.
11. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014;32:997-1005. Published online ahead of print December 3, 2013.
12. Chay WY, Tan SH, Lo YL, et al. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol 2010;6:270-277.
13. Dong M, Xing PY, Liu P, et al. Assessment of the protective effect of calciummagnesium infusion and glutathione on oxaliplatin-induced neurotoxicity [in Chinese]. Zhonghua zhong Liu Za Zhi 2010;32:208-211.
14. Ishibashi K, Okada N, Miyazaki T, et al. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 2010;15:82-87.
15. Wallace PJ, Shah ND, Dennen T, et al. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 2014;33:1187-1194.
16. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-5334.
17. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
18. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011;29:3214-3223.
19. Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-1224.
20. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006;6:152-156.
21. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8:387-394.